PL3908270T3 - Połączenie dekstrometomorfanu i bupropionu do leczenia depresji u pacjentów pochodzenia azjatyckiego - Google Patents

Połączenie dekstrometomorfanu i bupropionu do leczenia depresji u pacjentów pochodzenia azjatyckiego

Info

Publication number
PL3908270T3
PL3908270T3 PL20737928.0T PL20737928T PL3908270T3 PL 3908270 T3 PL3908270 T3 PL 3908270T3 PL 20737928 T PL20737928 T PL 20737928T PL 3908270 T3 PL3908270 T3 PL 3908270T3
Authority
PL
Poland
Prior art keywords
dextromethorphan
bupropion
combination
treating depression
asian patients
Prior art date
Application number
PL20737928.0T
Other languages
English (en)
Inventor
Herriot TABUTEAU
Original Assignee
Antecip Bioventures Ii Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Antecip Bioventures Ii Llc filed Critical Antecip Bioventures Ii Llc
Publication of PL3908270T3 publication Critical patent/PL3908270T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/485Morphinan derivatives, e.g. morphine, codeine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL20737928.0T 2019-01-07 2020-01-07 Połączenie dekstrometomorfanu i bupropionu do leczenia depresji u pacjentów pochodzenia azjatyckiego PL3908270T3 (pl)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962789431P 2019-01-07 2019-01-07
US201962789488P 2019-01-07 2019-01-07
US201962789451P 2019-01-07 2019-01-07
US201962789446P 2019-01-07 2019-01-07
PCT/US2020/012612 WO2020146412A1 (en) 2019-01-07 2020-01-07 Combination of dextromethorphan and bupropion for treating depression

Publications (1)

Publication Number Publication Date
PL3908270T3 true PL3908270T3 (pl) 2026-02-16

Family

ID=71521902

Family Applications (1)

Application Number Title Priority Date Filing Date
PL20737928.0T PL3908270T3 (pl) 2019-01-07 2020-01-07 Połączenie dekstrometomorfanu i bupropionu do leczenia depresji u pacjentów pochodzenia azjatyckiego

Country Status (28)

Country Link
EP (2) EP4631571A3 (pl)
JP (1) JP2022516361A (pl)
KR (2) KR20210110654A (pl)
CN (4) CN114712358A (pl)
AU (3) AU2020207261B2 (pl)
BR (1) BR112020025902A2 (pl)
CA (2) CA3223187A1 (pl)
CL (1) CL2021001810A1 (pl)
CO (1) CO2021008988A2 (pl)
CR (1) CR20210368A (pl)
DK (1) DK3908270T3 (pl)
EC (1) ECSP21051833A (pl)
ES (1) ES3051232T3 (pl)
FI (1) FI3908270T3 (pl)
HR (1) HRP20251402T1 (pl)
IL (1) IL284663A (pl)
LT (1) LT3908270T (pl)
MX (1) MX2021008247A (pl)
MY (1) MY201603A (pl)
NZ (1) NZ777261A (pl)
PE (1) PE20212249A1 (pl)
PL (1) PL3908270T3 (pl)
PT (1) PT3908270T (pl)
RS (1) RS67453B1 (pl)
SG (1) SG11202106392RA (pl)
SI (1) SI3908270T1 (pl)
SM (1) SMT202600055T1 (pl)
WO (1) WO2020146412A1 (pl)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12109178B2 (en) 2013-11-05 2024-10-08 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11433067B2 (en) 2013-11-05 2022-09-06 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11534414B2 (en) 2013-11-05 2022-12-27 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US12194006B2 (en) 2013-11-05 2025-01-14 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11969421B2 (en) 2013-11-05 2024-04-30 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US12569479B2 (en) 2016-05-25 2026-03-10 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
KR20210110654A (ko) * 2019-01-07 2021-09-08 안테씨프 바이오벤쳐스 투 엘엘씨 우울증 치료를 위한 덱스트로메토르판과 부프로피온의 조합
US20250073188A1 (en) 2020-06-05 2025-03-06 Antecip Bioventures Ii Llc Compounds and combinations thereof for treating neurological and psychiatric conditions
US12472156B2 (en) 2020-06-05 2025-11-18 Antecip Bioventures Ii Llc Compounds and combinations thereof for treating neurological and psychiatric conditions
US12433884B2 (en) 2020-06-05 2025-10-07 Antecip Bioventures Ii Llc Compounds and combinations thereof for treating neurological and psychiatric conditions
KR20230113787A (ko) 2020-12-01 2023-08-01 안테씨프 바이오벤쳐스 투 엘엘씨 우울증 환자의 자살 위험 감소를 위한 부프로피온 및덱스트로메토르판
JP2024526896A (ja) * 2021-07-21 2024-07-19 アンテシップ バイオベンチャーズ トゥー エルエルシー うつ病の治療
CN117813083A (zh) * 2021-08-09 2024-04-02 安泰赛普生物风投二代有限责任公司 维持抑郁症状缓解的方法
CN119212709A (zh) * 2022-05-17 2024-12-27 安泰赛普生物风投二代有限责任公司 抑郁的治疗
US12156914B2 (en) 2022-06-30 2024-12-03 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising bupropion and cysteine
US12036191B1 (en) 2022-06-30 2024-07-16 Antecip Bioventures Ii Llc Treatment of poor metabolizers of dextromethorphan with a combination of bupropion and dextromethorphan
US11717518B1 (en) 2022-06-30 2023-08-08 Antecip Bioventures Ii Llc Bupropion dosage forms with reduced food and alcohol dosing effects
US11844797B1 (en) 2023-04-20 2023-12-19 Antecip Bioventures Ii Llc Combination of dextromethorphan and bupropion for treating depression
US12194036B2 (en) 2022-07-07 2025-01-14 Antecip Bioventures Ii Llc Combination of dextromethorphan and bupropion for treating depression
US11730706B1 (en) 2022-07-07 2023-08-22 Antecip Bioventures Ii Llc Treatment of depression in certain patient populations
WO2025117954A1 (en) * 2023-12-01 2025-06-05 Axsome Therapeutics, Inc. Compounds and combinations thereof for treating depression in patients

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2641392A1 (en) * 2006-02-03 2007-08-16 Avanir Pharmaceuticals Pharmaceutical compositions for treating depression, anxiety and neurodegenerative disorders
SG11201502425WA (en) * 2012-10-11 2015-05-28 Ix Biopharma Ltd Solid dosage form
WO2014120936A2 (en) * 2013-01-30 2014-08-07 Pharmorx Therapeutics, Inc. Treatments for depression and other diseases with a low dose agent
US10512643B2 (en) * 2013-11-05 2019-12-24 Antecip Bioventures Ii Llc Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
CN110327338A (zh) * 2013-11-05 2019-10-15 安泰赛普生物风投二代有限责任公司 包含安非他酮或相关化合物和右美沙芬的组合物和方法
US9402843B2 (en) * 2013-11-05 2016-08-02 Antecip Bioventures Ii Llc Compositions and methods of using threohydroxybupropion for therapeutic purposes
CN117427077A (zh) * 2014-09-14 2024-01-23 阿瓦尼尔制药股份有限公司 用于治疗痴呆中的激越行为的包含右美沙芬化合物和奎尼丁的药物组合物
PT3220909T (pt) * 2014-11-21 2020-12-07 Antecip Bioventures Ii Llc Bupropiona para modular os níveis plasmáticos de fármaco de dextrometorfano
KR20210110654A (ko) * 2019-01-07 2021-09-08 안테씨프 바이오벤쳐스 투 엘엘씨 우울증 치료를 위한 덱스트로메토르판과 부프로피온의 조합

Also Published As

Publication number Publication date
CA3126062A1 (en) 2020-07-16
CN112437659A (zh) 2021-03-02
MY201603A (en) 2024-03-05
ECSP21051833A (es) 2021-11-18
KR20240169131A (ko) 2024-12-02
NZ777261A (en) 2024-11-29
SI3908270T1 (sl) 2026-01-30
MX2021008247A (es) 2021-08-16
AU2025203831A1 (en) 2025-06-19
EP3908270A1 (en) 2021-11-17
RS67453B1 (sr) 2025-12-31
DK3908270T3 (da) 2025-11-17
KR20210110654A (ko) 2021-09-08
EP3908270A4 (en) 2022-02-16
WO2020146412A1 (en) 2020-07-16
CN112437659B (zh) 2022-04-12
PT3908270T (pt) 2025-11-12
EP3908270B1 (en) 2025-08-27
LT3908270T (lt) 2025-12-10
EP4631571A2 (en) 2025-10-15
CN114712358A (zh) 2022-07-08
CA3223187A1 (en) 2020-07-16
JP2022516361A (ja) 2022-02-25
PE20212249A1 (es) 2021-11-24
AU2023204348B2 (en) 2025-06-05
CA3126062C (en) 2024-02-06
HRP20251402T1 (hr) 2026-01-02
EP4631571A3 (en) 2025-11-26
AU2020207261B2 (en) 2023-04-13
SG11202106392RA (en) 2021-07-29
CR20210368A (es) 2021-12-10
CN114712357A (zh) 2022-07-08
CO2021008988A2 (es) 2021-09-09
ES3051232T3 (en) 2025-12-26
AU2023204348A1 (en) 2023-07-27
CN114712356A (zh) 2022-07-08
BR112020025902A2 (pt) 2021-07-13
FI3908270T3 (fi) 2025-11-24
SMT202600055T1 (it) 2026-03-09
CL2021001810A1 (es) 2022-03-04
AU2020207261A1 (en) 2021-07-08
IL284663A (en) 2021-08-31

Similar Documents

Publication Publication Date Title
SI3908270T1 (sl) Kombinacija dekstrometorfana in bupropiona za zdravljenje depresije pri azijskih bolnikih
GB2590793B (en) Cannabidiol-C1 for use as a medicament and in the treatment of epilepsy
SG10201908697XA (en) A pharmaceutical composition for use in the treatment or prevention of a c5-related disease and a method for treating or preventing a c5-related disease
PT3545948T (pt) Utilização de aglomerado de ouro ou substância que contém aglomerado de ouro na preparação de droga para prevenção e/ou tratamento de glaucoma
IL282871A (en) Systems and methods for skin care
EP3250609A4 (en) Il13ra alpha 2 binding agents and use thereof in cancer treatment
SG10202002898RA (en) A Pharmaceutical Composition For Use In The Treatment Or Prevention Of A C5-Related Disease And A Method For Treating Or Preventing A C5-Related Disease
SG11202108331XA (en) Adjustable expiratory relief in respiratory therapy
IL266623A (en) A pharmaceutical preparation for use in the therapeutic treatment of cancer and complications of cancer
GB2588994B (en) Combar for skin and hair treatment
EA201390287A1 (ru) Теобромин в комбинации с отхаркивающим или муколитическим средствами для применения в терапии
EP3848032A4 (en) APPLICATION OF PYRROLOQUINOLINE QUINONE IN THE PREPARATION OF A MEDICINE USED FOR PREVENTING AND TREATING ACUTE ALTITUDE SICKNESS AND ACUTE ALTITUDE HYPOXIC INJURY
GB201919200D0 (en) Use of mir-12 in preparation of drugs for treating intrauterine adhesion and/or thin endometrum
SG11202008914WA (en) A platform and system for use in therapeutic procedures
PT3937949T (pt) Fitoecdisonas e seus derivados para utilização no tratamento da alteração da função respiratória
ES3062513T3 (en) Factor ix variants and uses thereof in therapy
IL267534A (en) Low dose drug combinations for use in preventing and treating neuronal damage
ZA201806864B (en) Use of an acetylcholinesterase inhibitor and idalopirdine for reducing falls in parkinson's disease patients
ZA201804198B (en) Composition of olivetol and method of use reduce or inhibit the effects of tetrahydrocannabinol in the human body
PL3515399T3 (pl) Kompozycja kosmetyczna lub farmaceutyczna do pielęgnacji skóry, poprawy stanu skóry i redukcji zmarszczek
IL288905A (en) diagnosis and treatment
SG11202112877XA (en) Surface treatment agent and method for manufacturing surface treatment body
SG11202107221UA (en) Curved needle and curved catheter
SG11202000509PA (en) Nanostructured and biocompatible biocatalysts for use in cancer treatment
HK40075731A (en) Lnp-formulated mrna therapeutics and use thereof for treating human subjects